COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA

被引：1
|
作者：
Alhammad, A. [1 ]
Lecca, Garrido S. [2 ]
机构：
[1] King Abdul Aziz Med City, Riyadh, Saudi Arabia
[2] Bristol Myers Squibb, Dubai, U Arab Emirates
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2254
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
下载
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [11] Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
    Sakai, H.
    Nishio, M.
    Hida, T.
    Nakagawa, K.
    Nogami, N.
    Atagi, S.
    Takahashi, T.
    Nokihara, H.
    Saka, H.
    Takenoyama, M.
    Fujita, S.
    Tanaka, H.
    Takeda, K.
    Satouchi, M.
    Isobe, H.
    Maemondo, M.
    Goto, K.
    Hirashima, T.
    Minato, K.
    Tamura, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S111
  • [12] COST-UTILITY OF NIVOLUMAB AGAINST DOCETAXEL FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN UNITED ARAB EMIRATES (UAE)
    Lecca, Garrido S.
    Alhammad, A.
    Dawood, S.
    VALUE IN HEALTH, 2017, 20 (05) : A112 - A113
  • [13] Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective
    Fuming Li
    Yingyao Chen
    Dunming Xiao
    Shan Jiang
    Yi Yang
    Advances in Therapy, 2024, 41 : 1436 - 1449
  • [14] Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective
    Li, Fuming
    Chen, Yingyao
    Xiao, Dunming
    Jiang, Shan
    Yang, Yi
    ADVANCES IN THERAPY, 2024, 41 (04) : 1436 - 1449
  • [15] Cost-Effectiveness of Pemetrexed for Advanced Non-Squamous Non-Small Cell Lung Cancer (nsNSCLC) in Patients Treated in a Spanish Institution
    Mielgo Rubio, Xabier
    Martinez Cabanes, Ruth
    Velastegui, Alejandro
    Rosero, Adriana
    Ruiz-Gimenez, Leticia
    Aguayo, Cristina
    Garcia Ferron, Maria
    Silva, Jorge
    Perez Fernandez, Elia
    Jara, Carlos
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S419 - S419
  • [16] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
  • [17] Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
    Ben Rothwell
    Christopher Kiff
    Caroline Ling
    Thor-Henrik Brodtkorb
    PharmacoEconomics - Open, 2021, 5 : 251 - 260
  • [18] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [19] A COST-EFFECTIVENESS ANALYSIS OF FIRST LINE INDUCTION AND MAINTENANCE TREATMENT SEQUENCES IN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UNITED STATES
    Kumar, G.
    Woods, B.
    Winfree, K. B.
    Boye, M. E.
    Hess, L. M.
    Bryden, P. A.
    Koustenis, A.
    Treat, J.
    VALUE IN HEALTH, 2014, 17 (03) : A82 - A82
  • [20] Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
    Rothwell, Ben
    Kiff, Christopher
    Ling, Caroline
    Brodtkorb, Thor-Henrik
    PHARMACOECONOMICS-OPEN, 2021, 5 (02) : 251 - 260
12345